Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3246-3256

  DeNardo, Gerald L ^a   DeNardo, Sally J ^a   Goldstein, Desiree S ^a   Kroger, Linda A ^a   Lamborn, Kathleen R ^a   Levy, Norman B ^a   McGahan, John P ^a   Salako, Qansy ^a   Shen, Sui ^a   Lewis, Jerry P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER REGRESSION; CLINICAL ARTICLE; DOSIMETRY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

EID: 0031759837     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3246     Document Type: Article

References (69)

1. Moxley JH, DeVita VT, Brace K: Intensive combination chemotherapy and x-irradiation in Hodgkin's disease. Cancer Res 27:1258-1263, 1976
2. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Coiffier B, Byron PA, Ffrench M, et al: Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival. Blood 70:1394-1399, 1987
4. Longo DL, Duffey PL: Management of aggressive histology lymphoma: An approach based on data from the National Cancer Institute. Hematol Oncol Ann 1:19-28, 1993
5. Gordon LI, Harrington D, Anderson J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349, 1992
6. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1:17-33, 1988
7. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 2:49-53, 1987
8. Scheinberg DA, Strauss DJ, Yeh SD, et al: A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol 8:792-803, 1990
9. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
10. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
11. Czuczman MS, Straus DJ, Divgi CR, et al: Phase 1 doseescalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11:2021-2029, 1993
12. Knox SJ, Levy R, Miller RA, et al: Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50:4935-4940, 1990
13. 90Y lymphoma therapy. Cancer 73:966-973, 1994 (suppl)
14. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj Radiopharm 6:1-11, 1993
15. Kuzel T, Rosen ST, Zimmer AM, et al: A phase 1 escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother 8:3-16, 1993
16. 131I-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 5:562-573, 1985
17. Parker BA, Vassos AB, Halpern SE, et al: Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res 50:1022-1028, 1990
18. Goldenberg DM, Horowitz JA, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548-564, 1991
19. Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 9:918-928, 1991
20. Scheinberg DA, Lovett D, Divgi CR, et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478-490, 1991
21. DeNardo GL, Lewis JP, DeNardo SJ, et al: Effect of Lym-1 Madioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425-1432, 1994
22. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer 3:96-101, 1988 (suppl)
23. 131I-Lym-1. Cancer Res 50:1014-1016, 1990 (suppl)
24. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 60:85-100, 1991
25. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
26. Evans ML, Graham MM, Mahler PA, et al: Changes in vascular permeability following thorax irradiation in the rat. Radiat Res 107:262-271, 1986
27. Warhoe KA, DeNardo SJ, Wolkov HB, et al: Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer. Antibody Immunoconj Radiopharm 5:227-235, 1992
28. Msirikale JS, Klein JL, Schroeder J, et al: Radiation enhancement of radiolabeled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 13:1839-1844, 1987
29. Kalofonos H, Rowlinson G,Epenetos AA: Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res 50:159-163, 1990
30. DeNardo SJ, Mirick GR, Kroger LA, et al: The biologic window for chimeric L6 radioimmunotherapy. Cancer 73:1023-1032, 1994 (suppl)
31. Schlom J, Molinolo A, Simpson JF, et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763-771, 1990
32. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 41:127-134, 1988
33. Buchsbaum DJ, Khazaeli MB, Liu TP, et al: Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res 55:5881-5887, 1995 (suppl)
34. Meredith RF, Khazaeli MB, Liu T, et al: Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33:1648-1653, 1992
35. Siegel JA, Wessels BW, Watson EE, et al: Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 3:213-233, 1990
36. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 14:587-595, 1993
37. Lim S-M, DeNardo GL, DeNardo DA, et al: Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med 38:1374-1378, 1997
38. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971
39. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982
40. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
41. Rose LM, Gunasekera AH, DeNardo SJ, et al: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 43:26-30, 1996
42. Epstein AL, Marder RJ, Winter JN, et al: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830-840, 1987
43. Hu E, Epstein AL, Naeve GS, et al: A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155-166, 1989
44. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, World Health Organization, 1979
45. DeNardo GL, Raventos A, Hines HH, et al: Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 11:335-348, 1985
46. Erwin WD, Groch MW, Macey DJ, et al: A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 23:525-532, 1996
47. DeNardo DA, DeNardo GL, Yuan A, et al: Prediction of radiation doses from therapy using tracer studies with iodine-131 labeled antibodies. J Nucl Med 37:1970-1975, 1996
48. Loevinger R, Berman M: A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1. New York, NY, Society of Nuclear Medicine, 1976
49. Snyder WS, Ford MR, Warner GG: "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York, NY, Society of Nuclear Medicine, 1975
50. DeNardo GL, DeNardo SJ: Overview of obstacles and opportunities for radioimmunotherapy of cancer, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1994, pp 141-154
51. DeNardo GL, DeNardo SJ: Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer, in Burchiel SW, Rhodes BA (eds): Radioimmunoimaging and Radioimmunotherapy. New York, NY, Elsevier Science, 1983, pp 41-62
52. Wessels BW, Vessella RL, Palme DF, et al: Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 17:1257-1263, 1989
53. Langmuir VK, McGann JK, Buchegger F, et al: The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids. Nucl Med Biol 18:753-764, 1991
54. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
55. 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998 (in press)
56. Nias AHW: Fractionated radiotherapy, in An Introduction to Radiobiology. Chichester, United Kingdom, Wiley, 1990, pp 256-276
57. 131I-Lym-1 and mechanisms for improvement, in Epenetos A (ed): Monoclonal Antibodies 2, Applications in Clinical Oncology. New York, NY, Chapman & Hall Medical, 1993, pp 355-367
58. Dillman RO, Beauregard JC, Jamieson M, et al: Toxicities associated with monoclonal antibody infusions in cancer patients. Mol Biother 1:81-85, 1988
59. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
60. DeNardo GL, Lamborn KR, Goldstein DS, et al: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer 80:2706-2711, 1997 (suppl)
61. Lamborn KR, DeNardo GL, DeNardo SJ, et al: Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 3:1253-1260, 1997
62. DeNardo GL, Lamborn KR, DeNardo SJ, et al: Prognostic factors for radioimmunotherapy in patients with B-Lymphocytic malignancies. Cancer Res 55:5893-5898, 1995 (suppl)
63. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757-765, 1986
64. Fowler JF: Radiobiological aspects of low dose rates in radioimmunotherapy. Im J Radiat Oncol Biol Phys 18:1261-1269, 1990
65. Knox SJ, Goris ML,Wessels BW: Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 23:111-117, 1992
66. Winthrop MD, DeNardo SJ, Muenzer JT, et al: p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 80:2706-2712, 1997 (suppl)
67. Farber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist,4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238:787-793, 1948
68. Yourtes A, Sarris A, Melnyk A, et al: Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:583-587, 1995
69. DeNardo SJ, Kukis DL, Kroger LA, et al: Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 94:4000-4004, 1997